P2D Bioscience
Specialty pharmaceutical company focused on discovery and preclinical development of small-molecule drugs for central nervous system inflammatory and neurodegenerative disorders (notably frontotemporal dementia and Alzheimer’s disease) and dopamine-transporter–targeted therapies for ADHD. The company uses targeted phenotypic screening and transgenic animal models to advance orally active, CNS-penetrant small-molecule candidates through preclinical efficacy, safety/toxicology (non-GLP and planned GLP) and early clinical proof-of-concept studies, with the intent to partner for later-stage clinical development and commercialization.
Industries
Nr. of Employees
small (1-50)
P2D Bioscience
2180 East Galbraith Rd, Bldg. D, Rm. 124, Cincinnati, OH 45237
Products
Orally active CNS-penetrant TNFα synthesis inhibitors (preclinical candidates)
Small-molecule inhibitors that reduce TNFα by inhibiting TNFα mRNA synthesis; demonstrated reduction of central and plasma TNFα, prevention of tau-inclusion pathology and mitigation of cognitive/behavioral deficits in transgenic preclinical models.
Centrally active dopamine-transporter inhibitors (benztropine-analog series, preclinical candidates)
Benztropine-analog small molecules optimized for improved dopamine transporter affinity and central activity; evaluated in preclinical biochemical and behavioral proof-of-concept studies for ADHD indications.
Orally active CNS-penetrant TNFα synthesis inhibitors (preclinical candidates)
Small-molecule inhibitors that reduce TNFα by inhibiting TNFα mRNA synthesis; demonstrated reduction of central and plasma TNFα, prevention of tau-inclusion pathology and mitigation of cognitive/behavioral deficits in transgenic preclinical models.
Centrally active dopamine-transporter inhibitors (benztropine-analog series, preclinical candidates)
Benztropine-analog small molecules optimized for improved dopamine transporter affinity and central activity; evaluated in preclinical biochemical and behavioral proof-of-concept studies for ADHD indications.
Expertise Areas
- CNS drug discovery and development
- Preclinical models of neurodegeneration
- Medicinal chemistry and SAR optimization
- Biomarker development and pharmacodynamic assays
Key Technologies
- Targeted phenotypic screening
- Transgenic rodent models of neurodegeneration
- Behavioral and cognitive preclinical assays
- Medicinal chemistry and SAR